Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1573-1578

  Warren, Samantha ^a,b   Partridge, Mike ^a,b   Fokas, Emmanouil ^a,b   Eccles, Cynthia L ^a,b   Brunner, Thomas B ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER PROGRAM; DOSE VOLUME HISTOGRAM; GASTROINTESTINAL TOXICITY; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LETTER; MATHEMATICAL MODEL; NORMAL TISSUE COMPLICATION PROBABILITY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; RADIOLOGICAL PARAMETERS; THREE DIMENSIONAL RADIOTHERAPY; TREATMENT PLANNING; TUMOR VOLUME; DUODENUM; KIDNEY; PANCREAS CANCER; RADIATION DOSE; SMALL INTESTINE; STOMACH VOLUME; STOMACH WALL;

HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; NEOPLASM STAGING; ORGANS AT RISK; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84884571221     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.813072     Document Type: Letter

References (24)

1. Jemal A, Siegel R, WarDe, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96
2. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy fi ndings. J Gastrointest Surg 2006;10:511-8
3. Spalding A C, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, et al. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007;34:521-9
4. Abelson JA, Murphy JD, Minn A Y, Chung M, Fisher GA, Ford JM, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012;82:e595-601
5. Sangalli, G, Passoni P, Cattaneo GM, Broggi S, Bettinardi V, Reni M, et al. Planning design of locally advanced pancreatic carcinoma using 4DCT anDiMRT/IGRT technologies. Acta Oncol 2011;50:72-80
6. Landry JC, Yang GY, Ting JY, Staley CA, Torres W, Esiashvili N, et al. Treatment of pancreatic cancer tumors with intensitymodulated radiation therapy (IMRT) using the volume at risk approach (VARA): Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim 2002;27:121-9
7. Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, et al. A phase I/II triaLof intensity modulated radiation (IMRT) dose escalation with concurrent fi xed-dose rate gemcitabine (FDR-G) in patients witHunresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:1166-71
8. Eppinga W, Lagerwaard F, Verbakel W, Slotman B, Senan S. Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 2010;186:382-7
9. Ali AN, Dhabaan AH, Jarrio CS, Siddiqi AK, Landry JC. Dosimetric comparison of volumetric modulated arc therapy anDintensity-modulated radiation therapy for pancreatic malignancies. Med Dosim 2012;37:271-5
10. Vieillot S, Azria D, Riou O, Moscardo CL, Dubois JB, Ailleres N, et al. Bilateral kidney preservation by volumetricmodulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol 2011;6:147
11. Scorsetti M, BignardIm, Alongi F, Fogliata A, Mancosu P, Navarria P, et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results. Acta Oncol 2011;50:528-38
12. Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T, et al. Analysis of dosimetric parameters associated witHacute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy . Int J Radiat Oncol Biol Phys 2012;84:369-75
13. Liu M, Moiseenko V, AgranovicHa, Karvat A, Kwan W, Saleh ZH, et al. Normal tissue complication probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A test of the QUANTECfavored model. Int J Radiat Oncol Biol Phys 2010;78:S45-6
14. Fokas E, Eccles C, Patel N, Chu K-Y, Warren S, McKenna WG, et al. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiother Oncol 2013;107:200-6
15. Eccles C, Vallis K A, McKenna W, Brunner T, editors. 1 354 poster. Potential advantages and tradeoffs of intensity modulated radiotherapy for locally advanced pancreas cancer (including elective nodal volumes). Radiother Oncol 2011;99(SUPPL. 1):S506
16. Pan CC, Dawson LA, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced gastric and duodenal bleeds using thElyman-Kutcher-Burman model. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S217-8
17. Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012;83:1120-5
18. Roeske JC, Bonta D, Mell LK, Lujan A E, Mundt A J. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003;69:201-7
19. Li XA, Alber M, Deasy JO, Jackson A, Jee KWK, Marks LB, et al. The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPM(a). Med Phys 2012;39:1386-409
20. Sanchez-Nieto B, Nahum AE. B IOPLAN: Software for the biologicaLevaluation of. Radiotherapy treatment plans. Med Dosim 2000;25:71-6
21. Yovino S, Maidment B W, 3rd, Herman J M, Pandya N, Goloubeva O, Wolfgang C, et al. Analysis of local controLin patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012;83:916-20
22. CaravattAl, Sallustio G, Pacelli F, Padula GD, Deodato F, Macchia G, et al. Clinical target volume delineation including elective nodaLirradiation in preoperative and defi nitive radiotherapy of pancreatic cancer. Radiat Oncol 2012;7:86
23. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine L.S., Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76:S10-9
24. Burman C, Kutcher G J, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic-function. Int J Radiat Oncol Biol Phys 1991;21:123-35